Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
July 2017
-
A researcher seeks the roots of plants’ healing power
Deep in a forest in the West African country of Ghana, two men are searching for plants that they hope could ultimately provide a cure for some of the world’s deadliest diseases.
-
In The NewsIncreasing access to NCD treatments in UgandaNovartis reaches agreement with Uganda to supply medicines that address the rapid rise of chronic diseases in the country. Uganda becomes the fifth country to launch Novartis Access.
-
Media ReleaseNovartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasisLabel update includes 52 week data from CLEAR study demonstrating long-term superiority of Cosentyx® versus Stelara® in psoriasis [1],[2] Update also includes use of Cosentyx in moderate-to…
-
Featured NewsAlcon survey reveals that people are happier and more satisfied with their lives after cataract surgery
June 2017
-
Media ReleaseNovartis receives EU approval for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)In ALK-positive advanced NSCLC patients, Zykadia demonstrated superior median progression-free survival (PFS) compared to SOC chemotherapy with maintenance[1] Zykadia benefit was also seen…
-
Media ReleaseSandoz receives approval in Europe for Erelzi® (biosimilar etanercept) to treat multiple inflammatory diseasesEuropean Commission approves Sandoz Erelzi® to treat immunological diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis Approval of Erelzi provides more treatment options for…
-
A patient’s perspective on biomarker testing
A lung cancer patient describes her path to diagnosis and what came next.
-
Media ReleaseNEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)Significant overall survival benefit observed for FLT3+ AML patients consistent across FLT3 mutation subgroups, including ITD and TKD Detailed data show Rydapt plus standard chemotherapy improved…
-
From nurse to patient: facing an aggressive blood cancer
After being diagnosed with an aggressive form of leukemia, Ilana Massi defied the odds with the help of her friends and family.
-
Media ReleaseNovartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitorCHMP opinion based on pivotal Phase III trial that showed Kisqali plus letrozole reduced risk of disease progression or death by 44% over letrozole alone among postmenopausal women with HR+/HER2-…
-
Media ReleaseNovartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna®New 96-week data support durability and safety of Treatment-free Remission (TFR) in Ph+ CML-CP patients who stop taking Tasigna [1,2] More than 90% of Ph+ CML-CP patients in ENESTfreedom and ENESTop…
-
Media ReleaseNovartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data Data evaluating 63…
Pagination
- ‹ Previous page
- 1
- …
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- …
- 152
- › Next page